High-Affinity Antibody Selection Using FACS Cell Sorting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for generating high-affinity monoclonal antibodies are inefficient and require multiple rounds of screening or site-directed mutagenesis, limiting the throughput and availability of high-affinity antibodies.
Innovation Solution
A method for selecting and enriching high-affinity antibody-producing cells directly from a population using fluorescence-activated cell sorting (FACS) based on their binding properties, eliminating the need for time-consuming affinity selection and cloning steps.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If standard hybridoma technology is used to generate monoclonal antibodies, then antibody production is achieved, but the throughput and efficiency of isolating high affinity antibodies is limited
Solution Approach 1:
The patent applies preliminary action by performing affinity selection on primary antibody-producing cells before cloning and expression steps. Cells are screened for high affinity antibody production in vitro, and only those cells showing high affinity binding are selected for cloning and further development. This preliminary selection step eliminates the need for subsequent time-consuming affinity maturation processes.
Solution Approach 2:
The patent replaces traditional mechanical screening methods (such as ELISA-based panning or manual cell sorting) with fluorescence-activated cell sorting (FACS) technology. This substitution enables high-throughput, automated selection of high affinity antibody-producing cells based on fluorescent signal intensity, dramatically improving throughput and reducing labor requirements.
2Reliability
If multiple rounds of screening and site-directed mutagenesis are performed, then high affinity antibodies are obtained, but the time required for antibody generation increases
Solution Approach 1:
The patent performs affinity selection as a preliminary action on primary antibody-producing cells before cloning. By screening cells for high affinity antibody production at the cell level and selecting only those that produce high affinity antibodies, the patent eliminates the need for subsequent rounds of screening and mutagenesis, thereby reducing total development time while maintaining high reliability of antibody binding affinity.
Solution Approach 2:
The patent extracts and isolates only the primary antibody-producing cells that exhibit high affinity binding properties from the broader population of immunized cells. This extraction of high-affinity cells before cloning eliminates the need for time-consuming in vitro affinity maturation processes, directly reducing development time while preserving antibody reliability.
3Manufacturing precision
If antibody libraries are expressed in cell expression systems and then screened, then high quality protein libraries are produced, but the diversity of antibodies is limited
Solution Approach 1:
The patent applies self-service by utilizing the primary antibody-producing cells themselves as the source of diverse high affinity antibodies. Instead of relying on artificial expression systems that produce limited diversity, the method directly selects and clones from the natural diverse antibody repertoire of immunized animals, allowing the cells to serve as both the production system and the source of diversity.
Solution Approach 2:
The patent performs preliminary selection of high affinity antibody-producing cells from the natural diverse repertoire before cloning. This preliminary action preserves the inherent diversity of the original antibody population while ensuring that only high affinity clones are selected for further development, thereby maintaining both quality and diversity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the efficient isolation of high-affinity antibodies with binding affinities ranging from 0.1 pM to 10 nM, significantly reducing the number of steps and enhancing the probability of obtaining desirable antibodies.
Implementation Method 1
using fluorescence-activated cell sorting (FACS) based on their binding properties
Data Source
AI summary
The present disclosure relates to a method for identifying cells that express antigen-specific antibodies with a high binding affinity for a monomeric antigen. Using fluorescence activated cell sorting, cells expressing high affinity antigen-specific antibodies are selected from a population of immune cells isolated from a mammal that has been immunized with or otherwise exposed to the antigen. Nucleic acids encoding the high affinity antibodies can then be cloned into other lymphoid and non-lymphoid cells where the antibody can be expressed and from which the antibodies can be secreted.